Indeed, negative modulators of mGluR1 activity have already been used with some success in the treatment of ataxia symptoms in mouse models.21, 39 In an attempt to identify a readily available potential therapeutic compound, we selected Nitazoxanide, an FDA-approved drug, that was identified in a recent in silico-in vivo repositioning study as a negative allosteric modulator of mGluR1/540 and examined its ability to rescue the excessive mGluR1 signaling caused by the p.Tyr262Cys and p.Tyr792Cys missense variants in vitro. The gene discussed is GRM1; the disease is Ataxia.